Monte Carlo characterization of biocompatible beta‐emitting 90Y glass seed incorporated with the radionuclide 153Sm as a SPECT marker for brachytherapy applications. (6th September 2013)

• Record Type: Journal Article
• Authors: Hadadi, Asghar; Sadeghi, Mahdi; Sardari, Dariush; Khanchi, Alireza; Shirazi, Alireza
• Is Part Of: Journal of applied clinical medical physics. Volume 14:Number 5(2013)
• Page Start: 90
• Page End: 103
• Publication Date: 2013-09-06
• Subjects: brachytherapy -- dosimetry -- YAS glass -- TG‐60 protocol -- Monte Carlo simulation; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1120/jacmp.v14i5.4302
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract : A glass seed consisting of the β − ‐emitting radionuclide 90 Y incorporated with radionuclide 153 Sm as SPECT marker is proposed for potential application in brachytherapy in order to reduce the undesirable dose to healthy adjacent organs. The aim of this work is to determine the dosimetric characteristics, as suggested in the AAPM TG‐60/TG‐149 reports, for this seed using Monte Carlo simulation. Monte Carlo codes MCNP5, EGSnrc, and FLUKA were used to calculate the absorbed dose distribution around the seed. Dosimetric parameters, such as reference absorbed dose rate, radial dose function, and one‐dimensional (1D) and two‐dimensional (2D) anisotropy functions, were obtained. The computational results from these three codes are in agreement within 5.4% difference on average. The absorbed dose rate at the reference point was estimated to be 5.01 cGy h − 1 μ Ci − 1 and self absorption of YAS glass seed amounted to 30.51%. The results showed that, with thermal neutron bombardment of 5 hours in a typical flux, sufficient activity for applications in brachytherapy may be achieved. With a 5 mCi initial activity, the total dose of a YAS glass seed was estimated to be 1.38 Gy at 1.0 cm from the seed center. Comparing with gamma emitting seeds, the 90 Y seed could reduce undesirable doses to adjacent organs, because of the rapid dose falloff of beta ray. Because of the high R 90 value of 5.5 mm, fewer number of 90 Y seeds will be required for an interstitial brachytherapy treatment using permanent implant, in comparison with other beta‐emitting seeds. The results would be helpful in the development of the radioactive implants using 90 Y glass seeds for the brachytherapy treatment. PACS numbers: 87.53.Jw, 87.56.bg